Core Viewpoint - Xianjian Technology (01302) saw a stock increase of over 4%, closing at HKD 1.79 with a trading volume of HKD 37.76 million, following the approval of its innovative medical device by the National Medical Products Administration [1] Group 1: Product Approval - The Concave Supra integrated arch three-branch reconstruction system, co-developed by Professor Shu Chang from the National Center for Cardiovascular Diseases and Xianjian Technology, has been approved for entry into the special review procedure for innovative medical devices, known as the "green channel" for national innovation [1] - This marks the 17th product from Xianjian Technology to be approved for the national innovation "green channel" as an independently developed innovative product [1] Group 2: Product Features - The CS stent system is designed for minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, representing the world's first integrated three-branch reconstruction solution without brain ischemia [1] - The product will complement Xianjian's unique overall solution for endovascular treatment of aortic arch lesions, which includes innovative product matrices for chimney technology and in-situ fenestration technology, as well as the SureCham single-branch stent system [1]